Ογ½ΆΚΣΖ΅

Lindsey A. Fitzgerald
( out of 38 reviews )

Lindsey A. Fitzgerald, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-6906

Veterans Administration Medical Center

Salt Lake City

  • Dr. Lindsey Fitzgerald is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with chronic lymphocytic leukemia (CLL) and lymphomas. She also treats veterans at the George E. Wahlen Department of Veterans Affairs Medical Center in Salt Lake City. Her research interests include the management of aggressive non-Hodgkin lymphomas in the elderly population, outcomes for lymphomas treated with CAR T-cell therapy, and geographic variations in management and outcomes of aggressive lymphomas. Dr. Fitzgerald graduated from Dartmouth College and obtained her medical degree from Tufts Ογ½ΆΚΣΖ΅ School of Medicine prior to her training in Internal Medicine and Hematology/Oncology at the Ογ½ΆΚΣΖ΅ of Utah. She is board certified in both Hematology and Medical Oncology.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.8 /5
    ( out of 38 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 15, 2024
    HUNTSMAN CANCER CENTER

    Dr. Fitzgerald is a great doctor.

    October 13, 2024
    HUNTSMAN CANCER CENTER

    She's really caring and knowledgeable. Leukemia is hard but she's definitively helped us maintain a very positive attitude.

    October 05, 2024
    HUNTSMAN CANCER CENTER

    Dr. Fitzgerald was awesome, as was her PA

    September 28, 2024
    HUNTSMAN CANCER CENTER

    Dr Fitzgerald is professional and easy to talk to. She listens to my ?ΒΏs and answers them and is very easy to understand and relate to.

    September 21, 2024
    HUNTSMAN CANCER CENTER

    Listened to my concerns and took my suggestions into consideration.

    July 27, 2024
    HUNTSMAN CANCER CENTER

    Dr. Fitzgerald inspires trust and exhibits a truly caring attitude toward me and my wife. I am lucky and glad to have her as my oncologist

    July 27, 2024
    HUNTSMAN CANCER CENTER

    Dr Fitzgerald is awesome. She responded to me very quickly, even though I am a new patient for her. She was able to get me into the hospital that day and begin my chemo treatments the next day. Thank you, Dr Fitzgerald, for everything.

    July 20, 2024
    HUNTSMAN CANCER CENTER

    Obviously a well educated person who appears to think deeply on every question we raised. This goes for her support staff as well.

    July 14, 2024
    HUNTSMAN CANCER CENTER

    Dr. Fitzgerald is a remarkable Dr. She was so knowledgable about my history and me as a person.

    See More Patient Comments

  • Dr. Lindsey Fitzgerald is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with chronic lymphocytic leukemia (CLL) and lymphomas. She also treats veterans at the George E. Wahlen Department of Veterans Affairs Medical Center in Salt Lake City. Her research interests include the management of aggressive non-Hodgkin lymphomas in the elderly population, outcomes for lymphomas treated with CAR T-cell therapy, and geographic variations in management and outcomes of aggressive lymphomas. Dr. Fitzgerald graduated from Dartmouth College and obtained her medical degree from Tufts Ογ½ΆΚΣΖ΅ School of Medicine prior to her training in Internal Medicine and Hematology/Oncology at the Ογ½ΆΚΣΖ΅ of Utah. She is board certified in both Hematology and Medical Oncology.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - Ογ½ΆΚΣΖ΅ of Utah School of Medicine Fellow
    Residency Internal Medicine - Ογ½ΆΚΣΖ΅ of Utah School of Medicine Resident
    Professional Medical Medicine - Tufts Ογ½ΆΚΣΖ΅ School of Medicine M.D.
    Undergraduate Geography and Biology - Dartmouth College B.A.

    Selected Publications

    Journal Article

    1. Karmali R, Machhi R, Epperla N, Shouse G, Romancik JT, Moyo TK, Kenkre VP, Ollila TA, Fitzgerald LA, Hess BT, David KA, Roy I, Zurko JC, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin IA, Ma S, Moreira J, Winter JN, Pro B, Stephens DM, Danilov AV, Shah NN, Cohen JB, Barta SK, Torka P, Gordon LI (2024). Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell nHL Treated with CAR-T. Blood Adv, 8(10), 2592-2599. ()
    2. Melody M, Epperla N, Shouse G, Romancik JT, Allen PB, Moyo TK, Kenkre VP, Ollila TA, Fitzgerald LA, Hess BT, David KA, Herr MM, Odetola O, Lin AY, Moreira J, Ma S, Winter JN, Roy I, Stephens DM, Danilov AV, Shah NN, Barta SK, Cortese MJ, Cohen J, Gordon LI, Karmali R (2024). Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy. Blood Adv. ()
    3. Hansen AR, Vardell VA, Fitzgerald LA (2023). Epidemiologic Characteristics, Treatment Patterns, and Survival Analysis of Plasmablastic Lymphoma in the United States: A SEER and NCDB Analysis. Clin Lymphoma Myeloma Leuk. ()
    4. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032. ()
    5. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6. ()
    6. Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar M, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson SG, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade M, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J (2023). Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood Adv, 7(16), 4528-4538.
    7. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. Am J Hematol, 98(7), E172-E174. ()
    8. Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar M, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson SG, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade M, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J (2023). Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood Adv. ()
    9. Geoffrey Shouse, Andy Kaempf, Max J Gordan, Andy Artz, David Yashar, Audrey M Sigmund, Gordon Smilnak, Steven Bair, Agrima Mian, Lindsey Fitzgerald, Amneet Bajwa, Samantha Jaglowski, Neil Bailey, Mazyar Shadman, Kirsh Patel, Deborah Stephens, Manali Kamdar, Brian Hill, Jordan Gauthier, Reem Karmali, Loretta J Nastoupil, Adam S Kittai, Alexey B Danilov (2023). A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv, 2023(202301), 0016.
    10. Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV (2020). Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplant Cell Ther, 27(1), 46-52. ()
    11. Lee KM, Stott RT, Zhao G, SooHoo J, Xiong W, Lian MM, Fitzgerald L, Shi S, Akrawi E, Lei J, Deng S, Yeh H, Markmann JF, Kim JI (2014). TGF-Ξ²-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur J Immunol, 44(6), 1728-36. ()

    Review

    1. Sindt JE, Fitzgerald LA, Kuznicki J, Prelewicz S, Odell DW, Brogan SE (2023). Antiplatelet and Wound Healing Implications of Immunotherapy and Targeted Cancer Therapies in the Perioperative Period. [Review]. Anesthesiology, 139(4), 511-522. ()

    Case Report

    1. Fitzgerald L, Stephens DM (2020). Burkitt Lymphoma Presenting as Cranial Multineuritis Secondary to Primary Neurolymphomatosis: A Diagnostic Challenge. Clin Lymphoma Myeloma Leuk, 20(4), e201-e204. ()

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496. ()
    2. Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R (2023). Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. [Letter to the editor]. J Hematol Oncol, 16(1), 111. ()

    Abstract

    1. Imran Nizamuddin, Kevin A David, Jonathon B Cohen, Vaishalee P Kenkre, Geoffrey Shouse, Brian T Hess, Thomas A Ollila, Deborah M Stephens, Sayan Mullick Chowdhur, Robert Ferdman, Kaitlyn OShea, Jieqi Liu, Jason T Romancik, Joanna C Zurko, Rahul S Bhansali, Elyse I Harris, McKenzie Sorrell, Rebecca Masel, Lindsey Fitzgerald, Carlos Galvez, Shuo Ma, Jane N Winter, Barbara Pro, Leo I Gordon, Alexey V Danilov, Nirav N Shah, Stefan K Barta, Narendranath Epperla, Pallawi Torka, Reem Karmali (2023). Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. American Society of Hematology (ASH Publication) [Abstract]. Blood, (2021) 138 (Supplement 1)(532).
    2. Joanna C Zurko, Narendranath Epperla, Imran Nizamuddin, Pallawi Torka, Kevin A David, Thomas A Ollila, Brian T Hess, Jonathon B Cohen, Robert Ferdman, Jieqi Liu, Sayan Mullick Chowdhury, Kaitlyn OShea, Jason Romancik, Rahul Bhansali, Elyse Harris, Mckenzie Sorrell, Rebecca Masel, Lindsey Fitzgerald, Carlos Galvez, Shuo Ma, Jane N Winter, Barbara Pro, Leo I Gordon, Alexey V Danilov, Deborah M Stephens, Nirav N Shah, Geoffrey Shouse, Vaishalee P Kenkre, Stefan K Barta, Reem Karmali (2022). Outcomes and Treatment Patterns with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. American Society of Hematology (ASH) Annual Meeting [Abstract]. Blood, (2022)(140 (24)), 2584-2593.
    3. Geoffrey Shouse, Andy Kaempf, David Yashar, Audrey M Sigmund, Gordon Smilnak, Steven M Bair, Agrima Mian, Lindsey Fitzgerald, Amneet Bajwa, Samantha Jaglowski, Neil Bailey, Mazyar Shadman, Krish Patel, Deborah M Stephens, Manali Kamdar, Brian T Hill, Jordan Gauthier, Reem Karmali, Adam S Kittai, Alexey V Danilov (2022). Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter Review Study. American Society of Hematology (ASH) Annual Meeting [Abstract]. Blood, (2022) 140(Supplement 1), 2048-2050.
    4. Geoffrey Shouse, Andy Kaempf, Max J Gordan, David Yashar, Audrey M Sigmund, Gordon Smilnak, Steven M Bair, Agrima Mian, Lindsey A Fitzgerald, Amneet Bajwa, Samantha Jaglowski, Neli Bailey, Mazyar Shadman, Krish Patel, Deborah M Stephens, Manali Kamdar, Brian T Hill, Jordan Gauthier, Reem Karmali, Loretta J Nastoupil, Adam S Kittai, Alexey V Danilov (2022). Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study [Abstract]. 140(Supplement 1), 2048-2050.
    5. Daniel A Ermann, Victoria A Vardell, Manasa Velagapudi, Greer Burkholder, Lindsey A Fitzgerald, Mayur Narkhede, Harsh Shah, Lauren Shea, Adam Spivak, Deborah M Stephens, Boyu Hu, Gaurav Goyal (2022). Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy [Abstract]. 140(Supplement 1), 1076-1078.
    6. Ishan Roy, Narendranath Epperla, Geoggrey Shouse, Jason T Romancik, Tamara K Moyo, Vaishalee P, Kenkre, Thomas A Ollila, Lindsey A Fitzgerald, Brian T Hess, Andrew M Evens, Joanna Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S Bhansali, Elyse I Harris, McKenzie Sorrell, Jieqi Liu, Imran A Nizamuddin, Jonathan Moreira, Shuo Ma, Jane N Winter, Barabara Pro, Deborah M Stephens, Alexy B Danilov, Mirav N Shah, Jonathon B Cohen, Stefan K Barta, Pallawi Torka, Leo I Gordon, Reem Karmali (2022). Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy [Abstract]. 140(Supplement 1), 2416-2418.
    7. Charlotte B Wagner, Daniel A Ermann, Ken Boucher, Adrienne N Nedved, Ivan N Micallef, Sanjal H Desai, Haris Hatic, Gaurav Goyal, Erin Zacholski, Amanda Fegley, Audrey M Sigmund, David A Bond, Courtney Samules, Manali K Kamdar, Sheeba Ba Aqueel, Pallawi Torka, Kira MacDougall, Azra Borogovac, Sridevi Rajeeve, Suchitra Sundaram, Kalub Fedak, Dipenkumar, Modi, Elizabeth Travers, Sabarish Ayyappan, Nitin Chilakamarri, Elizabeth A Brem, Deborah M Stephens, Boyu Hu, Lindsey A Fitzgerald, Harsh Shah (2022). Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival [Abstract]. 140(Supplement 1), 9390-9392.
    8. Deborah M Stephens, Aaron Atkinson, James Jack Abbot, Marianne Bowling, Justin Williams Tony D Pomciter, Lindsey A Fitzgerald, David Wada (2022). High Prevalence of Beta-Human Papilloma Virus in Patients with Concurrent Chronic Lymphocytic Leukemia and Non-Melanoma Skin Cancer [Abstract]. 140(Supplement 1), 7053.
    9. Victoria A Vardell, Daniel A Ermann, Harsh Shah, Lindsey A Fitzgerald, Boyu Hu, Deborah M Stephens (2022). T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments [Abstract]. 140(Supplement 1), 1085-1086.
    10. Joanna Zurko, Geoffrey Shouse, Pallawi Torka, Tamara K Moyo, Jason T Romancik, Imran A Nizamuddin, Kaitlin Annunzio, Jieqi Liu, Stefan K Barta, Robert Ferdman, Rahul Bhansali, Jonathon B Cohen, Syan Mullick Chowdhurty, Nirav N Shah, Elyse I Harris, Vaishalee P Kenkre, McKenzie Sorrell, Brian T Hess, Deborah M Stephens, Lindsey A Fitzgerald, Thomas A Ollila, Ishan Roy, Shuo Ma, Jane N Winter, Barbara Pro, Jonathan Moreira, Leo I Gordon, Alexey V Danilov, Andrew M Evens, Narendranath Epperla, Reem Karmali (2022). Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy [Abstract]. 140(Supplement 1), 375-377.
    11. Daniel A Ermann, Victoria A Vardell, Lindsey A Fitzgerald, Harsh Shah, Boyu Hu, Deborah M Stephens (2022). Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia [Abstract]. 140(Supplement 1), 6668-6669.
    12. Patel S, Esther J, Sama S, Fitzgerald L (2022). From B to T: A case of concurrent B-cell and T-cell lymphomas successfully palliated with targeted therapies (2022). Association of VA Hematology/Oncology (AVAHO) National Meeting. [Abstract].
    13. Fitzgerald L, Sama S, Patel S, Ether J (2022). Waldenstrom’s Macroglobulinemia presenting as Schnitzler’s Syndrome [Abstract].
    14. Sama S, Fitzgerald L, Patel S (2022). Not Just Castleman Disease: an elusive diagnosis of TAFRO syndrome. Association of VA Hematology/Oncology (AVAHO) National Meeting. [Abstract].
    15. Victoria Vardell, Daniel Arthur Ermann, Harsh Shah, Lindsey Fitzgerald, Boyu Hu, Deborah M Stephens (2022). Survival outcomes in patients with chronic lymphocytic leukemia treated at academic centers [Abstract]. 40(Supplement 16), 7544.

  • Clinical Trials